MEMORY AND ATTENTION DISORDERS IN PATIENTS WITH MIGRAINE
Keywords:
migraine, diagnosis, migraine attacks, prevention, treatment, episodic migraine, chronic migraine, memory impairment.Abstract
The problem of migraine is widely discussed in the scientific literature. Currently, the criteria for diagnosis are clearly formulated, and there are numerous international recommendations for the relief of migraine attacks and its preventive treatment. It is well known that in episodic migraine (EM) and to an even greater extent chronic migraine (ChM), the ability to work of patients is seriously impaired [1]. Thus, in the two largest epidemiological studies at the moment, CaMEO and AMPP, the average level of disability on the MIDAS scale was extremely. It was high and amounted to 38-45 points among women with ChM and 6-7 points with EM [2]. At the same time, the proportion of patients with severe disability in EM is at the level of 32-38%, and in ChM reaches 79-82%. At the same time, traditionally, this disability is associated precisely with the presence of attacks of intense headache with EM and very frequent or constant pain with ChM.
References
Buse DC, Manack A, Serrano D, Turkel C, Lipton R. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2020;81(4):428-432.
Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: demographics and headache-related disability. Headache. 2022;56(8):1280-1289.
Gil-Gouveia R, Oliveira AG, Martins IP. A subjective cognitive impairment scale for migraine attacks. The MIG-SCOG: Development and validation. Cephalalgia. 2021;31:984-991. https://doi.org/10.1177/0333102411408359
Meyer JS, Thornby J, Crawford K, Rauch G. Reversible cognitive decline accompanies migraine and cluster headaches. Headache. 2020;40:638-646. https://doi.org/10.1046/j.1526-4610.2000.040008638.x
Quintela E, Castillo J, Munoz P, Pascual J. Premonitory and resolution symptoms in migraine: A prospective study in 100 unselected patients. Cephalalgia. 2016;26:1051-1060. https://doi.org/10.1111/j.1468-2982.2006.01157.x
Gil-Gouveia R, Oliveira AG, Martins IP. Cognitive dysfunction during migraine attacks: a study on migraine without aura. Cephalalgia. 2015;35(8):662-674. https://doi.org/10.1177/0333102414553823
Gil-Gouveia R, Martins I. Clinical description of attack-related cognitive symptoms in migraine: A systematic review. Cephalalgia. 2018;38(7):1335-1350. https://doi.org/10.1177/0333102417728250
Caro G, Caro JJ, O’Brien JA, Anton S, Jackson J. Migraine therapy: Development and testing of a patient preference questionnaire. Headache. 1998;38:602-607. https://doi.org/10.1046/j.1526-4610.1998.3808602.x
Huang L, Juan Dong H, Wang X, Wang Y, Xiao Zh. Duration and frequency of migraines affect cognitive function: evidence from neuropsychological tests and event-related potentials. J Headache Pain. 2017;18(1):54. https://doi.org/10.1186/s10194-017-0758-6
Costa A, Sansalone A, Squillace A, Vescio G, Iannacchero R. Self-referred cognitive impairment in migraine patients. J Headache Pain. 2015;16(suppl 1):149. https://doi.org/10.1186/1129-2377-16-s1-a149
Kamalova N.L. BOTULINUM THERAPY IN THE TREATMENT OF CHRONIC MIGRAINE. http://www.eijmr.org/index.php/eijmr/article/view/499
